New rapid blood test could slash unnecessary antibiotic use in sepsis
NCT ID NCT06069206
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a rapid blood test (T2Bacteria Panel) that identifies bacteria directly from blood, compared to standard blood cultures that take 1-3 days. Researchers wanted to see if using this test could help doctors stop unnecessary vancomycin (a strong antibiotic) sooner in 500 adults with suspected sepsis. The goal is to reduce side effects and antibiotic resistance while still treating infections effectively.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
T2Bacteria Panel (direct-from-blood bacterial test)
What this could lead to
If successful, this test could help doctors stop unnecessary antibiotics sooner, reducing side effects and antibiotic resistance.
What could go wrong
This is a single-center trial with 500 patients, so results may not apply everywhere. The test may not always be accurate, and faster antibiotic changes might not improve overall outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLOODSTREAM INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37203, United States